{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:35:25Z","timestamp":1777718125095,"version":"3.51.4"},"reference-count":38,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: For patients diagnosed with muscle-invasive bladder cancer (MIBC), prognosis remains poor with high rates of progression and risk for mortality. To better understand the current treatment landscape, this study aims to describe real-world treatment patterns and clinical outcomes for MIBC patients in Sweden.\nMaterials and methods: Using population-based registers and electronic medical records, patients with MIBC (T2-4aN0M0) were identified between January 2016 and December 2020 in the Sk\u00e5ne region in Sweden. Patients with de novo MIBC and those who progressed from high-risk nonmuscle-invasive bladder cancer were included. Treatment patterns, overall survival (OS), metastatic rate, event-free survival (EFS), and bladder-intact EFS (BI-EFS) were described.\u00a0\nResults: Among the 231 MIBC patients identified, 34% received only best supportive care (BSC) primarily due to age and comorbidity. Of the 153 patients who received curative treatment, 84 (55%) underwent radical cystectomy (RC) and 69 (45%) received bladder-sparing treatment. Patients who received bladder-sparing treatment were older, had poorer health status, and more comorbidities. Among RC-treated patients, 5-year OS and EFS were 74% (95% confidence interval [CI]: 61\u201383%) and 70% (95% CI: 58\u201379%), respectively. Among patients who received bladder-sparing treatment, 5-year OS and BI-EFS were 52% (95% CI: 38\u201364%) and 34% (95% CI: 21\u201348%), respectively.\nConclusions: Old age and high rates of comorbidities among the MIBC patient population meant many patients were ineligible for recommended RC and instead received bladder-sparing treatment or BSC only. High rates of progression and poor survival were observed in both patients undergoing RC and patients who received bladder-sparing treatment.<\/jats:p>","DOI":"10.2340\/sju.v60.43875","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:54:04Z","timestamp":1749714844000},"page":"108-114","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in Sweden"],"prefix":"10.2340","volume":"60","author":[{"given":"Kelvin H.M.","family":"Kwok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Abbadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Baculea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Spigelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Aly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frida","family":"Schain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"114833","unstructured":"752-sweden-fact-sheets.pdf. [cited 29-12-2023]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/752-sweden-fact-sheets.pdf"},{"key":"114834","doi-asserted-by":"crossref","unstructured":"Lobo N, Brooks NA, Zlotta AR, et al. 100 years of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18(10):611\u2013622. https:\/\/doi.org\/10.1038\/s41585-021-00481-1","DOI":"10.1038\/s41585-021-00481-1"},{"key":"114835","doi-asserted-by":"crossref","unstructured":"Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234\u2013241. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033","DOI":"10.1016\/j.eururo.2012.07.033"},{"key":"114836","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2020 Guidelines. Eur Urol. 2021;79(1):\u200b82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"114837","doi-asserted-by":"crossref","unstructured":"Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol. 2017;198(3):552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.\u200b04.086","DOI":"10.1016\/j.juro.2017.04.086"},{"key":"114838","doi-asserted-by":"crossref","unstructured":"Maibom SL, Joensen UN, Poulsen AM, et al. Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open. 2021;11(4):e043266. https:\/\/doi.org\/10.1136\/bmjopen-2020-043266","DOI":"10.1136\/bmjopen-2020-043266"},{"key":"114839","doi-asserted-by":"crossref","unstructured":"Kimura T, Ishikawa H, Kojima T, et al. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol. 2020;50(10):1097\u20131107. https:\/\/doi.org\/10.1093\/jjco\/hyaa155","DOI":"10.1093\/jjco\/hyaa155"},{"key":"114840","unstructured":"Nationellt v\u00e5rdprogram cancer i urinbl\u00e5sa, njurb\u00e4cken, urinledare och urinr\u00f6r \u2013 RCC Kunskapsbanken. [cited 6-3-2024]. Available from:https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/urinblase-och-urinvagscancer\/vardprogram\/"},{"key":"114841","doi-asserted-by":"crossref","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u2013655.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"114842","doi-asserted-by":"crossref","unstructured":"Carvalho FLF, Zeymo A, Egan J, et al. Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. Investig Clin Urol. 2020;61(4):390\u2013396. https:\/\/doi.org\/10.4111\/icu.2020.61.4.390","DOI":"10.4111\/icu.2020.61.4.390"},{"key":"114843","doi-asserted-by":"crossref","unstructured":"Cowan NG, Chen Y, Downs TM, et al. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol. 2014;2014:746298. https:\/\/doi.org\/10.1155\/2014\/746298","DOI":"10.1155\/2014\/746298"},{"key":"114844","doi-asserted-by":"crossref","unstructured":"Schiffmann J, Sun M, Gandaglia G, et al. Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. Minerva Urol Nefrol. 2017;69(2):173\u2013180. https:\/\/doi.org\/10.23736\/S0393-2249.16.02713-2","DOI":"10.23736\/S0393-2249.16.02713-2"},{"key":"114845","doi-asserted-by":"crossref","unstructured":"K\u00f6rner SK, Jensen JB. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013\u20132019. Scand J Urol. 2022;56(1):34\u201338. https:\/\/doi.org\/10.1080\/21681805.2021.2002400","DOI":"10.1080\/21681805.2021.2002400"},{"key":"114846","doi-asserted-by":"crossref","unstructured":"Eriksson V, Holmlund J, Wiberg E, et al. Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer-a Swedish retrospective multicentre study of a clinical database. Transl Androl Urol. 2022;11(8):1105\u20131115. https:\/\/doi.org\/10.21037\/tau-22-78","DOI":"10.21037\/tau-22-78"},{"key":"114847","doi-asserted-by":"crossref","unstructured":"Jerlstr\u00f6m T, Chen R, Liedberg F, et al. No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World J Urol. 2020;38(2):381\u2013388. https:\/\/doi.org\/10.1007\/s00345-019-02770-2","DOI":"10.1007\/s00345-019-02770-2"},{"key":"114848","doi-asserted-by":"crossref","unstructured":"Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer. 2014;120(11):1630\u20131638. https:\/\/doi.org\/10.1002\/cncr.28510","DOI":"10.1002\/cncr.28510"},{"key":"114849","doi-asserted-by":"crossref","unstructured":"Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):\u200b297\u2013303. https:\/\/doi.org\/10.1016\/j.eururo.2003.09.019","DOI":"10.1016\/j.eururo.2003.09.019"},{"key":"114850","doi-asserted-by":"crossref","unstructured":"Vlaming M, Kiemeney LALM, van der Heijden AG. Survival after radical cystectomy: progressive versus De novo muscle invasive bladder cancer. Cancer Treat Res Commun. 2020;25:100264. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100264","DOI":"10.1016\/j.ctarc.2020.100264"},{"key":"114851","doi-asserted-by":"crossref","unstructured":"Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666\u2013675. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.666","DOI":"10.1200\/JCO.2001.19.3.666"},{"key":"114852","doi-asserted-by":"crossref","unstructured":"H\u00e4ggstr\u00f6m C, Garmo H, de Luna X, et al. Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: a Swedish nationwide population-based cohort study. Cancer Med. 2019;8(5):2196\u20132204. https:\/\/doi.org\/10.1002\/cam4.2126","DOI":"10.1002\/cam4.2126"},{"key":"114853","doi-asserted-by":"crossref","unstructured":"Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol. 2015;67(6):1042\u20131050. https:\/\/doi.org\/10.1016\/j.eururo.2014.11.043","DOI":"10.1016\/j.eururo.2014.11.043"},{"key":"114854","doi-asserted-by":"crossref","unstructured":"Sabir EF, Holm\u00e4ng S, Liedberg F, et al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol. 2013;47(6):483\u2013490. https:\/\/doi.org\/10.3109\/21681805.2013.787118","DOI":"10.3109\/21681805.2013.787118"},{"key":"114855","doi-asserted-by":"crossref","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u2013866. https:\/\/doi.org\/10.1056\/NEJMoa022148","DOI":"10.1056\/NEJMoa022148"},{"key":"114856","doi-asserted-by":"crossref","unstructured":"Salminen AP, Koskinen I, Perez IM, et al. Neoadjuvant chemotherapy does not increase the morbidity of radical cystectomy: a 10-year retrospective nationwide study. Eur Urol Oncol. 2018;1(6):525\u2013530. https:\/\/doi.org\/10.1016\/j.euo.2018.06.014","DOI":"10.1016\/j.euo.2018.06.014"},{"key":"114857","doi-asserted-by":"crossref","unstructured":"Russell B, Liedberg F, Khan MS, et al. A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol. 2020;3(2):239\u2013249. https:\/\/doi.org\/10.1016\/j.euo.2019.09.008","DOI":"10.1016\/j.euo.2019.09.008"},{"key":"114858","doi-asserted-by":"crossref","unstructured":"Szabados B, Rodriguez-Vida A, Dur\u00e1n I, et al. Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS trial. Eur Urol Oncol. 2021;4(3):456\u2013463. https:\/\/doi.org\/10.1016\/j.euo.2020.11.010","DOI":"10.1016\/j.euo.2020.11.010"},{"key":"114859","doi-asserted-by":"crossref","unstructured":"Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-\u00adinvasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212\u2013222. https:\/\/doi.org\/10.1016\/j.eururo.2022.04.013","DOI":"10.1016\/j.eururo.2022.08.037"},{"key":"114860","doi-asserted-by":"crossref","unstructured":"Iacovino ML, Miceli CC, De Felice M, et al. Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint inhibitors. Int J Mol Sci. 2022;23(3):1133. https:\/\/doi.org\/10.3390\/ijms23031133","DOI":"10.3390\/ijms23031133"},{"key":"114861","doi-asserted-by":"crossref","unstructured":"de Ruiter BM, van de Kamp MW, van Steenbergen JPZ, et al. A multicenter retrospective cohort series of muscle-invasive bladder cancer patients treated with definitive concurrent chemoradiotherapy in daily practice. Eur Urol Open Sci. 2022;39:7\u201313. https:\/\/doi.org\/10.1016\/j.euros.2022.02.010","DOI":"10.1016\/j.euros.2022.02.010"},{"key":"114862","doi-asserted-by":"crossref","unstructured":"Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE \u2013 a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017;120(5):\u200b639\u2013650. https:\/\/doi.org\/10.1111\/bju.13900","DOI":"10.1111\/bju.13900"},{"key":"114863","doi-asserted-by":"crossref","unstructured":"Fahmy O, Khairul-Asri MG, Schubert T, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36(2):43\u201353. https:\/\/doi.org\/10.1016\/j.urolonc.2017.10.002","DOI":"10.1016\/j.urolonc.2017.10.002"},{"key":"114864","doi-asserted-by":"crossref","unstructured":"Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120\u2013137. https:\/\/doi.org\/10.1016\/j.eururo.2014.02.038","DOI":"10.1016\/j.eururo.2014.02.038"},{"key":"114865","doi-asserted-by":"crossref","unstructured":"Martini A, Sfakianos JP, Renstr\u00f6m-Koskela L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2020;125(2):270\u2013275. https:\/\/doi.org\/10.1111\/bju.14872","DOI":"10.1111\/bju.14872"},{"key":"114866","doi-asserted-by":"crossref","unstructured":"H\u00e4ggstr\u00f6m C, Hagberg O, G\u00e5rdmark T, et al. Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. BMJ Open. 2022;12(12):e064898. https:\/\/doi.org\/10.1136\/bmjopen-2022-064898","DOI":"10.1136\/bmjopen-2022-064898"},{"key":"114867","unstructured":"SNRUBC. [cited 29-10-2024]. Available from: https:\/\/statistik.incanet.se\/Urinblasecancer\/"},{"key":"114868","doi-asserted-by":"crossref","unstructured":"Oedorf K, Skaaheim Haug E, Liedberg F, et al. Perioperative management of radical cystectomy in the Nordic countries. Scand J Urol. 2019;53(1):51\u201355. https:\/\/doi.org\/10.1080\/21681805.2019.1583686","DOI":"10.1080\/21681805.2019.1583686"},{"key":"114869","doi-asserted-by":"crossref","unstructured":"Wiberg E, Vega A, Eriksson V, et al. A validation study of cT-Categories in the Swedish National Urinary Bladder Cancer Register-Norrland University Hospital. J Pers Med. 2023;13(7):1163. https:\/\/doi.org\/10.3390\/jpm13071163","DOI":"10.3390\/jpm13071163"},{"key":"114870","doi-asserted-by":"crossref","unstructured":"Wedholm A, Wiberg E, Styrke J, et al. Validation of clinical T stages and of prognostic negative markers in patients with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer Registry vs. data from a detailed research database. Transl Androl Urol. 2024;13(12):2757770\u20132752770. https:\/\/doi.org\/10.21037\/tau-24-454","DOI":"10.21037\/tau-24-454"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/43875\/50435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/43875\/50435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:54:22Z","timestamp":1749714862000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/43875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2340\/sju.v60.43875","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}